文献速递临床试验与 GCP

皮内针治疗类风湿关节炎:随机对照试验研究方案

Intradermal acupuncture for rheumatoid arthritis: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-07-14

本研究为随机假针安慰对照、患者结局评估者与统计师盲的试验,计划招募132例年龄≥18岁的类风湿关节炎(RA)患者,按1:1随机分配至皮内针(IA)组或假IA组,两组均接受RA基础治疗与护理常规。主要结局为治疗前后中医证候与健康评估问卷(HAQ)评分,次要结局为疾病活动度评分28(DAS28)与血清C反应蛋白(CRP)水平,旨在评估IA治疗RA的有效性与安全性。

要点

  • 皮内针治疗RA的疗效与安全性尚缺乏高质量证据,本试验采用随机假针盲法设计。
  • 计划纳入132例≥18岁RA患者,1:1随机分组,两组均接受基础治疗与护理。
  • 主要结局为中医证候与HAQ评分,次要结局为DAS28与血清CRP水平。

核心结论

  • 本试验旨在为皮内针治疗类风湿关节炎的有效性与安全性提供高质量证据。

研究设计与样本

  • 随机、假针安慰对照、患者结局评估者与统计师盲的试验,计划招募132例年龄≥18岁的RA患者。
  • 患者按1:1比例随机分配至皮内针组或假皮内针组,两组均接受RA基础治疗与护理常规。
  • 所有患者接受一个疗程治疗,即连续四次治疗,每次间隔1天。

关键数值与推荐

  • 主要结局为治疗前后中医证候与健康评估问卷(HAQ)评分。
  • 次要结局为疾病活动度评分28(DAS28)与血清C反应蛋白(CRP)水平。
  • 结局指标在治疗前与治疗后收集。

临床怎么用

  • 若证实有效且安全,皮内针或可作为RA的辅助治疗选择。
  • 研究结果可为临床实践中其他证型的选穴提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis (RA) is a common autoimmune disease that severely impacts quality of life. Currently available medications for the treatment of RA have adverse side effects. Emerging evidence suggests that intradermal acupuncture (IA) is feasible and safe for patients, but its application in RA patients has not been examined. Our study aims to explore the efficacy and safety of IA for the treatment of RA. METHODS: This study is a randomised, sham-controlled, patient-outcome assessor-statistician blind trial that aims to evaluate the effects of IA in patients with RA. We will recruit 132 patients aged ≥ 18 years with a diagnosis of RA. Patients will be randomly allocated with a 1:1 ratio to IA or sham IA groups. Both groups will receive basic treatment and nursing routines for RA. The experimental group will receive actual IA treatment, whereas the control group will receive sham IA treatment. All patients will receive one course of treatment (i.e., four consecutive treatment sessions with an intervening 1-day interval). Primary outcomes will be traditional Chinese medicine (TCM) syndromes before and after a treatment course and Health Assessment Questionnaire (HAQ) scores. Secondary outcomes will be disease activity score 28 (DAS28) and levels of serum C-reactive protein (CRP). Outcome measures will be collected pre- and post-treatment. DISCUSSION: This study aims to provide high-quality evidence for the efficacy and safety of IA for treating RA. In addition, the results will provide references for selection of acupoints for other syndromes in clinical practice. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000038028 . Registered on 8 September 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Luo H, Peng J, Ma Q, et al. Intradermal acupuncture for rheumatoid arthritis: study protocol for a randomised controlled trial. Trials. 2021. PMID: 34261530. doi:10.1186/s13063-021-05416-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。